Outset Medical, Inc. (OM) plunged 47.06% to $6.39, down $5.68, after reporting weaker-than-expected third-quarter 2025 results and cutting its full-year guidance.
The medical technology firm posted revenue of $29.4 million, a modest 3 percent year-over-year increase, but below analyst expectations due to slower system placements and deferred hospital capital spending.
The company reported a net loss of $32.7 million, or $0.66 per share, compared to a loss of $27.8 million, or $0.57 per share, a year earlier. Gross margin was 10.8 percent, down from 12.3 percent in the prior-year period, reflecting higher manufacturing and logistics costs.
Outset revised its 2025 revenue outlook to $115-$120 million, down from its prior forecast of $122-$126 million, citing slower adoption of its Tablo Hemodialysis System and hospital budget constraints. The company expects gross margins to remain pressured through early 2026 as it manages production scaling and cost structure.
CEO Leslie Trigg said Outset remains committed to its long-term growth strategy but acknowledged "near-term headwinds" in hospital purchasing trends.
On the day of the announcement, OM experienced unusually heavy trading volume as investors reacted to the disappointing results and guidance cut. The stock's 52-week range is $5.20 - $12.50.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.